Steve Kanters

Steve Kanters

Auto-generated profile, based on publicly available information

Steve Kanters

RainCity Analytics

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in eClinicalMedicine
Verified
Journal Article
Open access
SKSteve Kanters
Steve Kanters
MVMarco Vitoria
Marco Vitoria
MZMichael Zoratti
Michael Zoratti
MDMeg Doherty
Meg Doherty
MPMartina Penazzato
Martina Penazzato
NBNick Bansback
Nick Bansback
To inform World Health Organization (WHO) global guidelines, we updated and expanded the evidence base to assess the comparative efficacy, tolerability, and safety of first-line antiretroviral therapy (ART) regimens. We searched Embase, Medline and CENTRAL on 28 February 2020 to update the systematic literature review of clinical trials comparing recommended first-line ART that informed previous WHO guidelines. Outcomes included viral suppression, change in CD4 cell counts, mortality, serious and overall adverse events (AEs), discontinuation, discontinuations due to AEs (DAEs); and new outcomes: drug-resistance, neuropsychiatric AEs, early viral suppression, weight gain and birth outcomes. Comparative effects were assessed through network meta-analyses and certainty in the evidence was assessed using the GRADE framework. We identified 156 publications pertaining to 68 trials for the primary population. Relative to efavirenz, dolutegravir had improved odds of viral suppression across all time points (odds ratio [OR]: 1·94; 95% credible interval [CrI]: 1·48–2·56 at 96 weeks); was protective of drug-resistance (OR: 0·13; 95%CrI: 0·04–0·48); and led to fewer discontinuations (OR: 0·58; 95%CrI: 0·48–0·70). Evidence supported dolutegravir use among TB-HIV co-infected persons and pregnant women. Adverse birth outcomes were observed in 33.2% of dolutegravir-managed pregnancies and 35.0% of efavirenz-managed pregnancies. Low-dose efavirenz had comparable efficacy and safety to standard-dose efavirenz, but led to fewer DAEs (OR: 0·70; 95%CrI: 0·50–0·92). The evidence supports choosing dolutegravir in combination with lamivudine/emtricitabine and tenofovir disoproxil fumarate as the preferred first-line regimen and low-dose efavirenz-based regimens as an alternative. Dolutegravir can be considered to be effective, safe and tolerable. WHO.

23 September 2021
Verified
Book Chapter
Closed access
PDF file
SKSteve Kanters
Steve Kanters

27 October 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CJCaron A. Jacobson
Caron A. Jacobson
JMJavier Muñoz
Javier Muñoz
FSFang Sun
Fang Sun
SKSteve Kanters
Steve Kanters
ELEve H. Limbrick-Oldfield
Eve H. Limbrick-Oldfield
MDMichael Dickinson
Michael Dickinson
Chimeric antigen receptor (CAR) T-cell therapies, including axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), are innovative treatments for patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL). Following initial regulatory approvals, real-world evidence (RWE) of clinical outcomes with these therapies has been rapidly accumulating. Notably, several large registry studies have recently been published. Here, we comprehensively describe clinical outcomes with approved CAR T-cell therapies in patients with r/r LBCL using available RWE. We systematically searched EMBASE, MEDLINE, and 15 conference proceedings to identify studies published between 2017 and September 2022 that included ≥10 patients with r/r LBCL treated with commercially available CAR T-cell therapies. Eligible study designs were retrospective or prospective observational studies. Key outcomes of interest were objective response rate (ORR), complete response (CR) rate, overall survival (OS), progression-free survival (PFS), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). Random-effects meta-analyses were used to compare real-world outcomes with those of pivotal clinical trials and to compare clinical outcomes of axi-cel versus tisa-cel. Study cohort mapping was conducted to avoid including patients more than once. Of 76 cohorts we identified, 46 reported patients treated specifically with either axi-cel or tisa-cel, with 39 cohorts (n=2,754) including axi-cel and 20 (n=1,649) including tisa-cel. No studies of liso-cel that met the inclusion criteria were identified during the search period. Half of tisa-cel cohorts were European, whereas European cohorts accounted for 33% of axi-cel cohorts. Among studies with available data, axi-cel had a significantly shorter median time from apheresis to CAR T-cell infusion compared with tisa-cel. Despite including broader patient populations, real-world effectiveness and safety of axi-cel and tisa-cel were consistent with the pivotal clinical trials. Comparative meta-analysis of axi-cel versus tisa-cel demonstrated adjusted hazard ratios for OS and PFS of 0.60 (95% confidence interval [CI], 0.47-0.77) and 0.67 (95% CI, 0.57-0.78), respectively, both in favor of axi-cel. Odds ratios for ORR and CR rate, both favoring axi-cel over tisa-cel, were 2.05 (95% CI, 1.76-2.40) and 1.70 (95% CI, 1.46-1.96), respectively. Probabilities of Grade ≥3 CRS with axi-cel or tisa-cel were comparable, whereas axi-cel was associated with a higher incidence of Grade ≥3 ICANS (odds ratio: 3.95; 95% CI, 3.05-5.11). Our meta-analysis indicates that CAR T-cell therapies have manageable safety profiles and are effective in a wide range of patients with r/r LBCL, and that axi-cel is associated with improved OS and PFS and increased risk of Grade ≥3 ICANS compared with tisa-cel. Limitations of this study include nonrandomized treatments, potential unknown prognostic factors, and the lack of available real-world data for liso-cel.

12 May 2022 in eClinicalMedicine
Verified
Journal Article
Open access
SKSteve Kanters
Steve Kanters
FRFrancoise Renaud
Francoise Renaud
ARAjay Rangaraj
Ajay Rangaraj
KZKenneth Zhang
Kenneth Zhang
ELEve Limbrick-Oldfield
Eve Limbrick-Oldfield
MVMarco Vitoria
Marco Vitoria
This systematic review aimed to compare body weight gain associated outcomes over time between dolutegravir (DTG)-based antiretroviral (ART) regimens to other ART regimens, to compare tenofovir alafenamide (TAF)-based regimens, and to evaluate the associated prognostic factors. Systematic searches of MEDLINE, Embase, and CENTRAL for RCTs and observational studies comparing ART regimens were conducted on 13 September 2021. Outcomes of interest included: change in body weight, body mass index (BMI), waist circumference; and risk of hyperglycaemia and diabetes. Network meta-analyses were conducted at 12, 24, 48, 96 and 144 weeks using two networks differentiated by 3rd agents and backbone agents. The review identified 113 publications reporting on 73 studies. DTG-based regimens led to statistically higher weight gains than efavirenz-based regimens at all time points (mean difference: 1·99 kg at 96 weeks; 95% credible interval: 0·85–3·09) and was higher over time than low-dose efavirenz-, elvitegravir-, and rilpivirine-based regimens. They were comparable to raltegravir-, bictegravir- and atazanavir-based regimens. For backbones, TAF led to higher weight gain relative to tenofovir disoproxil fumarate (TDF), abacavir, and zidovudine. Prognostic factor analysis showed both low CD4 cell count and high HIV RNA viral load at baseline were consistently associated with higher weight gain, while sex was an effect modifier to African origins. DTG-based regimens lead to larger average weight gains than some other ART regimens and TAF leads to larger average weight gains than all other backbone antiretrovirals. Further research is needed to better understand long-term outcomes and their relationship to other metabolic outcomes. The WHO Global HIV, Hepatitis and Sexually Transmitted Infections Programmes.

25 August 2022 in Blood
Verified
Journal Article
Open access
PDF file
PGPaola Ghione
Paola Ghione
MPM. Lia Palomba
M. Lia Palomba
APAnik R. Patel
Anik R. Patel
SBSabela Bobillo
Sabela Bobillo
KDKevin Deighton
Kevin Deighton
JGJohn G. Gribben
John G. Gribben
In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients. Here, outcomes from ZUMA-5 are compared with the international SCHOLAR-5 cohort, which applied key ZUMA-5 trial eligibility criteria simulating randomized controlled trial conditions. SCHOLAR-5 data were extracted from institutions in 5 countries, and from 1 historical clinical trial, for r/r FL patients who initiated a third or higher line of therapy after July 2014. Patient characteristics were balanced through propensity scoring on prespecified prognostic factors using standardized mortality ratio (SMR) weighting. Time-to-event outcomes were evaluated using weighted Kaplan-Meier analysis. Overall response rate (ORR) and complete response (CR) rate were compared using weighted odds ratios. The 143 ScHOLAR-5 patients reduced to an effective sample of 85 patients after SMR weighting vs 86 patients in ZUMA-5. Median follow-up time was 25.4 and 23.3 months for SCHOLAR-5 and ZUMA-5. Median overall survival (OS) and progression-free survival (PFS) in SCHOLAR-5 were 59.8 months and 12.7 months and not reached in ZUMA-5. Hazard ratios for OS and PFS were 0.42 (95% confidence interval [CI], 0.21-0.83) and 0.30 (95% CI, 0.18-0.49). The ORR and CR rate were 49.9% and 29.9% in SCHOLAR-5 and 94.2% and 79.1% in ZUMA-5, for odds ratios of 16.2 (95% CI, 5.6-46.9) and 8.9 (95% CI, 4.3-18.3). Compared with available therapies, axi-cel demonstrated an improvement in meaningful clinical endpoints, suggesting axi-cel addresses an important unmet need for r/r FL patients. This trial was registered at www.clinicaltrials.gov as #NCT03105336.

13 January 2021 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
SKSteve Kanters
Steve Kanters
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
KTKristian Thorlund
Kristian Thorlund
AAAslam Anis
Aslam Anis
NBNick Bansback
Nick Bansback
Background: The use of individual patient data (IPD) in network meta-analyses (NMA) is rapidly growing. This study aimed to determine, through simulations, the impact of select factors on the validity and precision of NMA estimates when combining IPD and aggregate data (AgD) relative to using AgD only.Methods: Three analysis strategies were compared via simulations: 1) AgD NMA without adjustments (AgD-NMA); 2) AgD NMA with meta-regression (AgD-NMA-MR); and 3) IPD-AgD NMA with meta-regression (IPD-NMA). We compared 108 parameter permutations: number of network nodes (3, 5 or 10); proportion of treatment comparisons informed by IPD (low, medium or high); equal size trials (2-armed with 200 patients per arm) or larger IPD trials (500 patients per arm); sparse or well-populated networks; and type of effect-modification (none, constant across treatment comparisons, or exchangeable). Data were generated over 200 simulations for each combination of parameters, each using linear regression with Normal distributions. To assess model performance and estimate validity, the mean squared error (MSE) and bias of treatment-effect and covariate estimates were collected. Standard errors (SE) and percentiles were used to compare estimate precision.Results: Overall, IPD-NMA performed best in terms of validity and precision. The median MSE was lower in the IPD-NMA in 88 of 108 scenarios (similar results otherwise). On average, the IPD-NMA median MSE was 0.54 times the median using AgD-NMA-MR. Similarly, the SEs of the IPD-NMA treatment-effect estimates were 1/5 the size of AgD-NMA-MR SEs. The magnitude of superior validity and precision of using IPD-NMA varied across scenarios and was associated with the amount of IPD. Using IPD in small or sparse networks consistently led to improved validity and precision; however, in large/dense networks IPD tended to have negligible impact if too few IPD were included. Similar results also apply to the meta-regression coefficient estimates.Conclusions: Our simulation study suggests that the use of IPD in NMA will considerably improve the validity and precision of estimates of treatment effect and regression coefficients in the most NMA IPD data-scenarios. However, IPD may not add meaningful validity and precision to NMAs of large and dense treatment networks when negligible IPD are used.